CROS NT Announces its Expansion into German Market Creating CROS DE GmbH
Estimate enrich CROS NT with its expertise and a particular excellence concerning the oncology and dermatology-related research. Estimate was found in 1992 and is a privately held company led by Thomas Zwingers, who is Managing Director. Mr. Zwingers and now also Medical Scientific Director of CROS DE GmbH. Mr. Zwingers has worked in the field of clinical trial since 1980 and has an extremely wide experience in designing and evaluating clinical studies. He has also worked with approximately 70 publications, mostly with clinical partners. During his career he has managed the project team, performed statistical analyses and written statistical reports. In his new position at CROS DE GmbH, Mr. Zwingers will play a leading role in the operations, strategic planning, and corporate development of CROS’s growing portfolio of pharmaceuticals and biotechnology business.
CROS NT is a CRO specializing in clinical data management, statistical analysis, eCRF, ePRO and Life Science Application Hosting services. CROS NT was founded in 1993 and successfully implements high-quality and modern rapid execution applications of clinical study tasks. With CROS DE GmbH there is now the chance to expand CROS NT’s extensive knowledge into Europe.
CROS NT services relies on leading technologies, proven processes and employs experts to deliver on every project's specific requirements with a group of highly-qualified project managers and biostatisticians. The Verona Headquarters currently employs more than 40 people.
CROS NT has completed over 700 studies in a wide range of therapeutic areas like respiratory, oncology, cardiovascular, HIV and Infectious diseases of clinical and observational studies. The clients and partners are pharmaceuticals, biotechnology, medical device and academic organizations in Europe and USA. The reputation has been built on experience, quality, responsiveness to client needs and a passion to achieve the highest performance.
For further information please contact us at firstname.lastname@example.org or visit our website www.crosnt.com
CROS NT srl
Via Germania 2
Phone: +39 045 8202666
Fax: +39 045 8205875
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CROS NT Announces its Expansion into German Market Creating CROS DE GmbH here
News-ID: 122860 • Views: 1563
More Releases from CROS NT
CROS NT WINS A "BEST PRESENTATION" AT PhUSE 2010
Verona, Italy (26 NOVEMBER 2010) – Stefano Vezzoli, part of CROS NT’s highly qualified and experienced biostatistics team, won Best Presentation in the area of Statistics and Pharmacokinetics at the Pharmaceutical Users Software Exchange (PhUSE) conference in Berlin, Germany. Vezzoli’s presentation was titled “Inference for the Location Shift in 3x3 Crossover Studies: the Median-Scaling Method”. Vezzoli’s Paper Abstract In the case of non-normal study outcomes, a nonparametric approach may be used
CROS NT GROUP TO ATTEND THIRD ANNUAL ONCOLOGY CLINICAL TRIALS
Verona, Italy (23 NOVEMBER 2010) – The German subsidiary of the CROS NT Group, CROS DE GmbH, will be present at the Third Annual Oncology Clinical Trials in Munich, Germany from 29 November through 1 December. The therapeutic area of oncology is one of CROS NT’s areas of excellence regarding clinical trial experience, and the CROS DE management team is at the forefront of clinical trial consultancy in this field.
CROS NT Group launches Arithmos s.r.l. to keeping up with the new Innovation’s …
CROS NT Group launches Arithmos s.r.l., a start up company created at the beginning of 2010 with the aim to play an active role as information technology service provider within the pharmaceutical and biotechnology environment. Inheriting CROS NT’s 15 years experience and developing a strong sensibility for innovation investments, today Arithmos is a valuable partner to optimize companies performances and accelerate their growth into the market in an accurate, safe and
CROS NT appoints new Vice President for Germany
CROS NT (CRO) announces the appointment of Frank Freischläger as Vice President (VP) for CROS DE GmbH, the German affiliate of CROS NT. As a VP at CROS DE he will be responsible for all aspects, which is focused on successful clinical trial activities. CROS is very excited to adding Mr. Freischläger's depth of industry expertise to the CROS team. "Bringing someone of Frank's knowledge to an already strong team
More Releases for CRO
Imaging CRO Services Market: Competitive Dynamics & Global Outlook 2020-2025
Global Info Research offers a latest published report on Imaging CRO Services Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Imaging CRO Services Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. Click to view the full report TOC, figure
Global CRO Services Market Size, Status and Forecast
This report studies the global CRO Services market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global CRO Services market by companies, region, type and end-use industry. Contract research organization (CRO) provide clinical trial and other research support services for the pharmaceutical, biotechnology, medical device industries and also serve government institutions, foundations and universities. Get sample copy of the report: www.marketdensity.com/contact?ref=Sample&reportid=75298 Table of Contents: Table of Contents Global
Global Contract Research Organization (CRO) Market Developments and Innovations …
Qyresearchreports include new market research report "Global Contract Research Organization (CRO) Market Size,Status and Forecast 2025" to its huge collection of research reports. Contract research organization (CRO) provide clinical trial and other research support services for the pharmaceutical, biotechnology, medical device industries and also serve government institutions, foundations and universities. CROs provide drug development services, regulatory and scientific support, and infrastructure and staffing support to provide their clients with the flexibility to
Global CRO Services Market Size, Status and Forecast 2022
This report studies the global CRO Services market, analyzes and researches the CRO Services development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Sino Biological Inc. HCL Technologies CTMG, Inc. Powered Research, LLC? Blue Sky BioServices Biomapas Integrated Resources Inc ICON Plc Celsion Labs? Sample of this report is available upon request @ http://www.qyresearchreports.com/sample/sample.php?rep_id=1310184&type=E Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Market segment by
CRO Services Industry Worldwide Growth and Development
ReportsWeb.com has announced the addition of the “Global CRO Services Market Size, Status and Forecast 2022” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. This report studies the global CRO Services market, analyzes and researches the CRO Services development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in
Partnership factors in sponsor – CRO relationships
Drugs discovered today can realistically cost upwards of 900 million dollars and around 12 years of development to reach a market. CRO’s have been increasingly used by larger pharma to outsource their clinical research, allowing big pharma to shut down in-house R&D, in practice saving money. There have been some issues however with the outsourcing of trials to CROs, including serious relationship break down with negative attitudes, failure to communicate